A New Framework for Finding Type 1 Diabetes Before Symptoms Appear

For decades, Type 1 diabetes was identified only after symptoms appeared—when people experienced thirst, frequent urination, and fatigue. But research has shown that the disease develops silently in advance, marked by the appearance of autoantibodies: immune markers that attack the insulin-producing cells in the pancreas.

This shift in understanding has opened a new possibility: finding Type 1 diabetes before it causes symptoms. By detecting these autoantibodies early, doctors can identify who is at risk and monitor their progression over time. This preclinical stage offers a window of opportunity for future interventions and closer health monitoring.

A group of Spanish medical organizations—representing pediatricians, endocrinologists, and other specialists—developed an Integrated Care Pathway (ICP) to standardize how preclinical Type 1 diabetes is identified and managed. The pathway is based on current scientific evidence and expert consensus on best practices.

The framework is organized into four main components. First, identifying which populations should be screened. Second, detecting and confirming the presence of islet autoantibodies through testing. Third, providing clinical follow-up and staging—understanding how far the disease has progressed. Fourth, supporting all of this with reliable information systems and performance measures to track outcomes.

Without a coordinated system, screening for preclinical Type 1 diabetes can be inconsistent. Some patients might be tested, while others are missed. Follow-up care may vary widely. The new pathway aims to make the process uniform and reliable across different hospitals and clinics.

This structured approach also creates a clear process for staging—helping doctors understand whether someone has early autoimmunity or is closer to developing clinical symptoms. This information is essential for counseling families and planning future care.

By establishing a scalable, measurable framework, the pathway can be adapted and implemented across different regions, ensuring more people have access to early detection and monitoring.

Source: Anales de pediatria. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.